KDventures: Refinancing of Umecrine Results in Writedown - Redeye
Redeye comments on the latest funding round of Umecrine, resulting in a significantly lower book value. However, the dilution is moderate and we do not make any changes to our base case for now.
ANNONS
Redeye comments on the latest funding round of Umecrine, resulting in a significantly lower book value. However, the dilution is moderate and we do not make any changes to our base case for now.
